2025, Jilin Yatai (Group) Co., Ltd. issued the twelfth interim board resolution announcement in 2025. Three core bills involving asset disposal, financing and external guarantee were considered and passed by unanimous vote.
Yatai Bio-engineering was established in March 1994 with its registered address at No.8018, Beiyuanda Street, Changchun New District, Jilin Province. Its legal representative is Song Shuiyan. Its business scope includes pharmaceutical production, small volume injection, vaccine production, technical consultation, technical services, research and development, and its registered capital is RMB 181.2724 million. The Company holds 90,636,200 shares, accounting for 50% of the total share capital; Jilin Tairan Biotechnology Co., Ltd. holds 88,823,476 shares, accounting for 49% of the total share capital; Yatai Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the Company, holds 1,812,724 shares, accounting for 1% of the total share capital.
According to the audit report (Zhong Zhun Shen Zi [2025] No.2070) issued by Zhongzhun Certified Public Accountants (Special General Partnership) which meets the requirements of the Securities Law, as of December 31, 2024, the total assets of Yatai Biology were 55,031,762.61 yuan, and the total liabilities were 15,143,303.13 yuan. The net assets are 39,888,459.48 yuan, there is no operating income in 2024, and the net profit is -31,451,164.16 yuan.
As of June 30, 2025, Yatai Bio-engineering had total assets of 51,079,948.39 yuan, total liabilities of 15,460,149.73 yuan, net assets of 35,619,798.66 yuan, no operating income from January to June 2025, and net profit of -4,268,660.82 yuan.
According to the assets appraisal report (Zhong Ke Hua Ping Bao Zi [2025] No.047) issued by Beijing Zhongkehua Assets Appraisal Co., Ltd., which meets the requirements of the Securities Law, the book value of the owner's equity of Yatai Biology on the base date of appraisal is RMB 35.6198 million. The value of the total shareholders' equity appraised by the asset-based approach was RMB97.3177 million, with an appreciation amount of RMB61.7016 million and an appreciation rate of 173.24%.
According to the operation needs of its subsidiaries, the Company agreed to transfer 59.8 million shares of Yatai Biology directly held by the Company through public listing, with the base price of listing not less than 32.1042 million yuan (hereinafter referred to as the "Transaction"). The property right of the shares of Yatai Biology to be transferred in this transaction is clear, and there is no mortgage, pledge or any other restriction on transfer, no litigation, arbitration or judicial measures such as seizure and freezing, and no other circumstances that hinder the transfer of ownership. Upon completion
of the Transaction, the Company holds a total of 32,648,924 shares of Yatai Bio-engineering, with a total shareholding ratio of 18.01%, of which: the Company directly holds 30,836,200 shares, with a shareholding ratio of 17.01%; It indirectly holds 1,812,724 shares through its wholly-owned subsidiary Yatai Pharmaceutical Group Co., Ltd., with a shareholding ratio of 1%. Yatai Biology will no longer be included in the scope of the company's consolidated financial statements.
浙公网安备33010802003254号